Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCase Comprehensive Cancer Center

About this trial

Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.

Eligibility criteria

Qualifiers

Participants must have histologically, cytologically, or radiographically confirmed diagnosis of solid tumor with brain metastases

Age >18 years

Performance status: Karnofsky Performance Status (KPS) ≥ 70

Estimated life expectancy of at least 3 months

Disqualifiers

Prior whole brain radiation

Participant has Multiple Sclerosis, Alzheimer's, dementia, or mental disability

Pregnant or breastfeeding women are excluded from this study.

Participant is not able to receive an MRI

Trial design

Treatments tested in this trial

  • MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT))
  • HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT))
  • Memantine

Treatment groups

90 Participants
are divided into 2 treatment groups

Locations

1
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center44106, ClevelandOhio, United States

Sponsors and collaborators

Case Comprehensive Cancer Center

Lead sponsor